Bildkälla: Stockfoto

InDex Pharma Q4 2023: Trading below cash, but for how long…? - Redeye

Redeye update its view on InDex following the year-end report and with the current circumstances we see an interesting opportunity in the share.

Redeye update its view on InDex following the year-end report and with the current circumstances we see an interesting opportunity in the share.
Börsvärldens nyhetsbrev
ANNONSER